Takeda provides update on phase 3 panther (pevonedistat-3001) trial

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the phase 3 panther (pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (efs). the trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (mds), chronic myelomonocytic leukemia (cmml) an
TAK Ratings Summary
TAK Quant Ranking